Access Pharmaceuticals To Host Investor Call On Wednesday, July 31, 2013
DALLAS and NEW YORK, July 26, 2013 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, will host an investor call to update investors on recent company developments. The investor conference call is scheduled to be held on Wednesday, July 31, 2013 at 11:00 am ET. Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.
A replay of the call will be available starting on July 31, 2013 at 1:00 pm ET, through August 14, 2013 until 11:59 pm ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 377785.
About Access: Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access developed MuGard, a prescription oral rinse for the management of mucositis and is developing multiple products, and recently licensed US commercialization rights to AMAG Pharmaceuticals, Inc. Access also has other advanced drug delivery technologies including CobaCyte"-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals (ACCP.OB), please visit our website at www.accesspharma.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for MuGard and Cobalamin, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
Company and Media Contact:
Director of Investor Relations
Access Pharmaceuticals, Inc.
SOURCE Access Pharmaceuticals, Inc.